Pretransplant clinicopathological correlation in end-stage primary pulmonary hypertension.
The aim of the study was to see if there was any correlation between the histopathology, ultrastructure, pulmonary endocrinology and clinical manifestations of end-stage primary pulmonary hypertension. Twenty patients undergoing heart-lung transplantation for the disease were studied. The nature and duration of symptoms and signs, results of haematological, electrocardiographic, radiographic, echocardiographic and haemodynamic studies, and the response of patients to vasodilators were compared with data from histopathological and ultrastructural study of lungs removed at transplantation. Length of clinical history and clinical evidence of severe disease were not necessarily associated with advanced histopathology, nor did the presence of small, contracted muscular pulmonary arteries imply responsiveness to vasodilators. Numbers of gastrin-releasing peptide-containing pulmonary endocrine cells were greater in lungs in which there was activity of myofibroblasts in pulmonary arterial vessels, and correlated negatively with mean pulmonary artery pressure and pulmonary artery systolic pressure. Whereas the prognosis of primary pulmonary hypertension cannot as yet be defined by other than its clinical manifestations, intimal proliferation as well as vasoconstriction may be important in its pathogenesis. The release of gastrin-releasing peptide from pulmonary endocrine cells may possibly be involved in this process.
Madden
B P
BP
Harefield Hospital, Middlesex, UK.
Gosney
J
J
Coghlan
J G
JG
Kamalvand
K
K
Caslin
A W
AW
Smith
P
P
Yacoub
M
M
Heath
D
D
D000293:Adolescent; D000328:Adult; D002116:Calcitonin / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D005260:Female; D019886:Gastrin-Releasing Peptide; D005755:Gastrins / Q000378:metabolism; D016041:Heart-Lung Transplantation; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology / Q000601:surgery; D008168:Lung / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000378:metabolism; D014665:Vasodilator Agents / Q000627:therapeutic use
D005755:Gastrins; D010455:Peptides; D014665:Vasodilator Agents; D019886:Gastrin-Releasing Peptide; D002116:Calcitonin